07:00 , Mar 17, 2014 |  BC Week In Review  |  Company News

Bio-Matrix Scientific gene/cell therapy, hematology, cancer news

Bio-Matrix said that all shareholders on record as of March 18 will receive one share in subsidiary Regen BioPharma Inc. for every 147 Bio-Matrix shares held. Bio-Matrix plans to distribute 20 million of its 50...
07:00 , Oct 24, 2013 |  BC Innovations  |  Cover Story

A platform for RNA

An information explosion on the number of functional RNA molecules expressed in cells and the mechanisms by which they control gene expression 1,2 is driving the formation and funding of biotechs developing oligonucleotide-based therapeutics. Pharmas...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Company News

Benitec, Bio-Matrix Scientific deal

Benitec granted Bio-Matrix's Regen BioPharma Inc. subsidiary rights to Benitec's DNA-directed RNAi (ddRNAi) technology to silence indoleamine 2,3-dioyxgenase (INDO; IDO) in dendritic cells. Regen said that IDO is associated with immune suppression and is over-expressed...
07:00 , May 13, 2013 |  BC Week In Review  |  Company News

Bio-Matrix Scientific, University of Western Ontario deal

Bio-Matrix's Regen BioPharma Inc. subsidiary completed the acquisition of a patent from the university related to gene silencing technology to treat breast cancer. The acquired technology uses RNAi to inhibit indoleamine 2,3-dioxygenase (INDO; IDO). The...
08:00 , Mar 4, 2013 |  BC Week In Review  |  Company News

Bio-Matrix Scientific, University of Western Ontario deal

Bio-Matrix's Regen BioPharma Inc. subsidiary signed a letter of intent to acquire IP from the university related to gene silencing technology to treat breast cancer. The IP relates to the administration of nanoparticles to "train"...
07:00 , Jul 2, 2012 |  BC Week In Review  |  Company News

Bio-Matrix Scientific management update

Bio-Matrix Scientific Group Inc. (OTCQB:BMSN; Pink:BMSN), La Mesa, Calif.   Business: Transplant   Hired: Thomas Ichim as CSO and director of research at Bio-Matrix's Regen BioPharma Inc. subsidiary  ...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Company News

Bio-Matrix Scientific, Oregon Health & Science University deal

The university granted Bio-Matrix's Regen BioPharma Inc. subsidiary an exclusive, six-month option to license exclusive, worldwide rights to U.S. Patent No. 6,821,513 covering methods of stimulating blood production in patients with deficient stem cells. The...
07:00 , May 14, 2012 |  BC Week In Review  |  Company News

Bio-Matrix Scientific management update

Bio-Matrix Scientific Group Inc. (OTCQB:BMSN; Pink:BMSN), La Mesa, Calif.   Business: Transplant   Hired: Christopher Mizer as president and COO of Bio-Matrix's Regen BioPharma Inc. subsidiary  ...
07:00 , May 14, 2012 |  BC Week In Review  |  Company News

Bio-Matrix Scientific gene/cell therapy news

Bio-Matrix said it established subsidiary Regen BioPharma Inc. to develop stem cell therapies. Regen also secured $20 million in financing from Southridge Partners and identified three core technologies it intends to in license. The company...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Company News

Entest, Medistem deal

Entest announced it had signed a letter of intent to acquire about 61% of fellow stem cell company Medistem for $1 million in cash and $2 million in Entest shares. Thomas Ichim, CEO of Medistem,...